BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 12917760)

  • 1. Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia.
    Ott K; Weber WA; Fink U; Helmberger H; Becker K; Stein HJ; Müller J; Schwaiger M; Siewert JR
    World J Surg; 2003 Sep; 27(9):1035-9. PubMed ID: 12917760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
    Lorenzen S; von Gall C; Stange A; Haag GM; Weitz J; Haberkorn U; Lordick F; Weichert W; Abel U; Debus J; Jäger D; Münter MW
    BMC Cancer; 2011 Jun; 11():266. PubMed ID: 21702914
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Schneider PM; Eshmuminov D; Rordorf T; Vetter D; Veit-Haibach P; Weber A; Bauerfeind P; Samaras P; Lehmann K
    BMC Cancer; 2018 May; 18(1):548. PubMed ID: 29743108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Response to Neoadjuvant Chemoradiotherapy by 18F-FDG PET/CT in Patients With Locally Advanced Esophagogastric Junction Adenocarcinoma.
    Sánchez-Izquierdo N; Perlaza P; Pagès M; Buxó E; Rios J; Rubello D; Colletti PM; Mayoral M; Casanueva S; Fernández-Esparrach G; Ginés A; Fuster D
    Clin Nucl Med; 2020 Jan; 45(1):38-43. PubMed ID: 31714278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction.
    Wieder HA; Ott K; Lordick F; Becker K; Stahl A; Herrmann K; Fink U; Siewert JR; Schwaiger M; Weber WA
    Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1925-32. PubMed ID: 17680242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.
    Ott K; Weber WA; Lordick F; Becker K; Busch R; Herrmann K; Wieder H; Fink U; Schwaiger M; Siewert JR
    J Clin Oncol; 2006 Oct; 24(29):4692-8. PubMed ID: 16966684
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Lehmann K; Eshmuminov D; Bauerfeind P; Gubler C; Veit-Haibach P; Weber A; Abdul-Rahman H; Fischer M; Reiner C; Schneider PM
    Eur J Surg Oncol; 2017 Jan; 43(1):196-202. PubMed ID: 27692533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of diffusion-weighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction.
    Weber MA; Bender K; von Gall CC; Stange A; Grünberg K; Ott K; Haberkorn U; Kauczor HU; Zechmann C
    J Gastrointestin Liver Dis; 2013 Mar; 22(1):45-52. PubMed ID: 23539390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging.
    Weber WA; Ott K; Becker K; Dittler HJ; Helmberger H; Avril NE; Meisetschläger G; Busch R; Siewert JR; Schwaiger M; Fink U
    J Clin Oncol; 2001 Jun; 19(12):3058-65. PubMed ID: 11408502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualized surgical strategies for cancer of the esophagogastric junction.
    Stein HJ; Feith M; Siewert JR
    Ann Chir Gynaecol; 2000; 89(3):191-8. PubMed ID: 11079787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.
    Lordick F; Ott K; Krause BJ; Weber WA; Becker K; Stein HJ; Lorenzen S; Schuster T; Wieder H; Herrmann K; Bredenkamp R; Höfler H; Fink U; Peschel C; Schwaiger M; Siewert JR
    Lancet Oncol; 2007 Sep; 8(9):797-805. PubMed ID: 17693134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to classify adenocarcinomas of the esophagogastric junction: as esophageal or gastric cancer?
    Gertler R; Stein HJ; Loos M; Langer R; Friess H; Feith M
    Am J Surg Pathol; 2011 Oct; 35(10):1512-22. PubMed ID: 21934477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perioperative EOX treatment in operable locally advanced gastroesophageal adenocarcinoma: Prediction of tumor response by FDG -PET and histopathology.
    Vihervaara H; Ålgars A; Kemppainen J; Sundström J; Ristamäki R; Salminen P
    Surg Oncol; 2019 Mar; 28():42-49. PubMed ID: 30851910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a role for PET/CT with esophagogastric junction adenocarcinoma?
    Fuster D; Mayoral M; Rubello D; Pineda E; Fernández-Esparrach G; Pagès M; Colletti PM; Pons F
    Clin Nucl Med; 2015 Mar; 40(3):e201-7. PubMed ID: 25546207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical resection for cancer of the cardia.
    Siewert JR; Stein HJ; Sendler A; Fink U
    Semin Surg Oncol; 1999 Sep; 17(2):125-31. PubMed ID: 10449684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of baseline FDG-PET/CT scan as a method of staging regional lymph nodes in patients with operable distal oesophageal or gastroesophageal junction adenocarcinoma.
    Papaxoinis G; Weaver JMJ; Khoja L; Patrao A; Stamatopoulou S; Alchawaf A; Owen-Holt V; Germetaki T; Kordatou Z; Mansoor W
    Acta Oncol; 2017 Sep; 56(9):1224-1232. PubMed ID: 28524708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification.
    Siewert JR; Feith M; Stein HJ
    J Surg Oncol; 2005 Jun; 90(3):139-46; discussion 146. PubMed ID: 15895452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinomas of the esophagogastric junction.
    von Rahden BH; Stein HJ; Feith M; Becker K; Siewert JR
    J Clin Oncol; 2005 Feb; 23(4):874-9. PubMed ID: 15681533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction.
    Wieder HA; Beer AJ; Lordick F; Ott K; Fischer M; Rummeny EJ; Ziegler S; Siewer JR; Schwaiger M; Weber WA
    J Nucl Med; 2005 Dec; 46(12):2029-34. PubMed ID: 16330567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic response evaluation by PET during neoadjuvant treatment for adenocarcinoma of the esophagus and esophagogastric junction.
    Sendler A
    Recent Results Cancer Res; 2010; 182():167-77. PubMed ID: 20676880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.